Cysteine linked nanobody dimers

Patent metadata

Field	Value
Publication number	US-12384835-B2
Application number	US-202217850339-A
Country	US
Kind code	B2
Filing date	Jun 27, 2022
Priority date	Dec 19, 2014
Publication date	Aug 12, 2025
Grant date	Aug 12, 2025

Abstract

The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.

First claim

The invention claimed is:

1. A method for making a dimer, comprising:
(i) providing a first polypeptide, wherein said first polypeptide comprises
at least one immunoglobulin single variable domain (ISVD) and
a C-terminal extension comprising a cysteine moiety;

(ii) providing a second polypeptide, wherein said second polypeptide comprises
at least one immunoglobulin single variable domain (ISVD) and
a C-terminal extension comprising a cysteine moiety; and

(iii) oxidizing the thiol moiety of said cysteine moiety of said first polypeptide and the thiol moiety of said cysteine moiety of said second polypeptide to a disulfide derivative cystine;
characterized in that the integrity of the ISVDs is maintained and said cystine is the only intermolecular disulfide bond present in the dimer;
thereby making said dimer;
wherein the C-terminal extension of the first polypeptide consists of 1 to 50 amino acids and/or the C-terminal extension of the second polypeptide consists of 1 to 50 amino acids;
wherein the C-terminal amino acid of the first polypeptide is not cysteine and/or the C-terminal amino acid of the second polypeptide is not cysteine; and
wherein the method further comprises reducing the first polypeptide and the second polypeptide prior to (i) by incubating said first polypeptide and said second polypeptide in conditions comprising 1-15 mM dithiothreitol (DTT).

2. The method according to claim 1 , further comprising the step of purifying said dimer.

3. The method according to claim 1 , wherein said first polypeptide and said second polypeptide are identical.

4. The method according to claim 1 , wherein said first polypeptide and said second polypeptide are different.

5. The method according to claim 4 , wherein (i) comprises providing a plurality of first polypeptides, wherein the first polypeptides are bound to a carrier and (ii) comprises providing a plurality of second polypeptides, and wherein at least 80% of said first and said second polypeptides are dimerized in (iii).

6. The method according to claim 1 , wherein said first polypeptide and/or said second polypeptide comprises a C-terminal extension of 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid residue(s).

7. The method according to claim 1 , wherein the C-terminal extension of the first polypeptide is genetically fused to the C-terminal end of the most C-terminally located ISVD in said polypeptide, and wherein the C-terminal extension of the second polypeptide is genetically fused to the C-terminal end of the most C-terminally located ISVD in said polypeptide.

8. The method according to claim 1 , wherein (iii) comprises adding copper ions (Cu2+) at pH 6.5 to pH 7.5.

9. The method of claim 8 , wherein (iii) comprises incubating the first polypeptide and the second polypeptide in 0.1-10 mM CuSO 4 .

10. The method according claim 1 , wherein the first polypeptide comprises a C-terminal extension consisting of 2 to 10 amino acids, wherein the most C-terminal amino acid of the first polypeptide is not cysteine.

11. The method according to claim 1 , wherein the second polypeptide comprises a C-terminal extension consisting of 2 to 10 amino acids, wherein the most C-terminal amino acid of the second polypeptide is not cysteine.

12. The method according to claim 1 , further comprising conjugating said dimer to an imaging agent or to a cytotoxic drug, wherein the cytotoxic drug is chosen from the group consisting of: cytostatic agents; cytotoxic agents; chemotherapeutic agents; growth inhibitory agents; toxins, optionally an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof; toxin moieties; and radioactive isotopes.

13. A method for making a dimer, comprising:
(i) providing a plurality of first polypeptides under reducing conditions, wherein the first polypeptides are bound to a carrier, and wherein each of said first polypeptides comprises
at least one immunoglobulin single variable domain (ISVD) and
a C-terminal extension comprising a cysteine moiety;

(ii) providing a plurality of second polypeptides, wherein each of said second polypeptides comprises
at least one immunoglobulin single variable domain (ISVD) and
a C-terminal extension comprising a cysteine moiety; and

(iii) oxidizing a thiol moiety of said cysteine moiety of at least one of said first polypeptides and a thiol moiety of said cysteine moiety of at least one of said second polypeptides to a disulfide derivative cystine, thereby making said dimer,
wherein the integrity of the ISVDs in the dimer is maintained and said cystine is the only intermolecular disulfide bond present in the dimer;
wherein the C-terminal extension of each of the first polypeptides consists of 1 to 50 amino acids and/or the C-terminal extension of each of the second polypeptides consists of 1 to 50 amino acids; and
wherein the C-terminal amino acid of each of the first polypeptides is not cysteine and/or the C-terminal amino acid of each of the second polypeptides is not cysteine.

14. The method of claim 13 , wherein (ii) comprises flowing the plurality of second polypeptides over the plurality of first polypeptides bound to the carrier under oxidizing conditions according to (iii).

15. The method of claim 14 , further comprising (iv) recovering non-conjugated second polypeptides, reducing said non-conjugated second polypeptides, and flowing the non-conjugated second polypeptides over the first polypeptides bound to the carrier under oxidizing conditions.

16. The method of claim 15 , further comprising (v) recovering the dimer from the carrier.

17. The method according to claim 13 , wherein the method further comprises reducing the first polypeptides and second polypeptides prior to (i) by incubating said first polypeptides and said second polypeptides in conditions comprising 1-15 mM dithiothreitol (DTT).

18. The method of claim 13 , further comprising (iv) recovering the dimer from the carrier.

19. The method of claim 14 , further comprising (iv) recovering the dimer from the carrier.

Assignees

• Ablynx Nv

Inventors

• Janssen Daniel
• Schotte Peter
• Descamps Francis
• Boutton Carlo
• Casteels Peter

Classifications

• C07K16/468

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• C07K16/3015

  Breast · CPC title

• C07K16/30

  from tumour cells · CPC title

• C07K1/16

  by chromatography · CPC title

• A61K51/1096

  radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications · CPC title